<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <Volume-Issue>Volume 3; Issue 6</Volume-Issue>
      <Season>(Nov-Dec, 2022)</Season>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Avoiding The Severe Gastrointestinal Side Effects Associated with High Dose Potassium and Magnesium Supplementation with Gitelman’s Syndrome Through Utilization of Canagliflozin, Aliskiren and Spironolactone</ArticleTitle>
          <FirstName>David S. H.</FirstName>
      <Abstract>Gitelman’s Syndrome is an inherited renal tubulopathy that is characterized by renal potassium and magnesium wasting leading to hypokalemia and hypomagnesemia. Previously the only available therapies for the hypokalemia and hypomagnesemia associated with Gitelman’s Syndrome were high dose oral potassium and magnesium supplements. With the availability of the SGLT-2 receptor blocker canagliflozin the need for magnesium replacement therapy can be minimized. Similarly, utilizing blockade of the renin and mineralocorticoid receptors with aliskiren and spironolactone respectively the need for oral potassium replacement can be avoided. By eliminating or reducing the need for oral potassium and magnesium replacement therapy, gastrointestinal problems, particularly diarrhea, can be avoided and the quality of life improved while achieving normal serum potassium and magnesium levels. In addition, by normalizing serum potassium and particularly by correcting serum magnesium levels, the risk of a cardiac arrythmia is also reduced.</Abstract>
      <Keywords>Gitelman's Syndrome,Hypomagnesemia,Hypokalemia,Canagliflozin,Aliskiren,Spironolactone</Keywords>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=14143&amp;title=Avoiding The Severe Gastrointestinal Side Effects Associated with High Dose Potassium and Magnesium Supplementation with Gitelman’s Syndrome Through Utilization of Canagliflozin, Aliskiren and Spironolactone</Abstract>
        <References>Bell DS. Successful utilization of aliskiren, a direct renin inhibitor in Bartter syndrome. South Med J 2009; 102: 413-415.&#13;
Blanchard A, Bockenhauer D, Bolignano D, Caland;ograve; LA, Cosyns E, Devuyst O, Ellison DH, Karet Frankl FE, Knoers NV, Konrad M, Lin SH, Vargas-Poussou R. Gitelman syndrome: consensus and guidance from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017; 91: 24-33.&#13;
Burch GE and Giles TD. The importance of magnesium deficiency in cardiovascular disease. Am Heart J 1977; 94: 649-657.&#13;
Del Gobbo LC, Song Y, Poirier P, Dewailly E, Elin RJ, Egeland GM. Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes. Cardiovasc Diabetol 2012; 11: 23.&#13;
Fichman MP, Telfer N, Zia P, Speckart P, Golub M, Rude R. Role of prostaglandins in the pathogenesis of Bartterand;#39;s syndrome. Am J Med 1976; 60: 785-797.&#13;
Fulchiero R and Seo-Mayer P. Bartter Syndrome and Gitelman Syndrome. Pediatr Clin North Am 2019; 66: 121-134.&#13;
Gilbert RE, Mende C, Vijapurkar U, Sha S, Davies MJ, Desai M. Effects of Canagliflozin on Serum Magnesium in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Ther 2017; 8: 451-458.&#13;
Iseri LT, Freed J, Bures AR. Magnesium deficiency and cardiac disorders. Am J Med 1975; 58: 837-846.&#13;
Kieboom BC, Niemeijer MN, Leening MJ, van den Berg ME, Franco OH, Deckers JW, Hofman A, Zietse R, Stricker BH, Hoorn EJ. Serum Magnesium and the Risk of Death From Coronary Heart Disease and Sudden Cardiac Death. J Am Heart Assoc 2016; 5: e002707.&#13;
Konrad M, Nijenhuis T, Ariceta G, Bertholet-Thomas A, Calo LA, Capasso G, Emma F, Schlingmann KP, Singh M, Trepiccione F, Walsh SB, Whitton K, Vargas-Poussou R, Bockenhauer D. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int 2021; 99: 324-335.&#13;
Mrad FCC, Soares SBM, de Menezes Silva LAW, Dos Anjos Menezes PV, Simand;otilde;es-E-Silva AC. Bartterand;#39;s syndrome: clinical findings, genetic causes and therapeutic approach. World J Pediatr 2021; 17: 31-39.&#13;
Pachulski RT, Lopez F, Sharaf R. Gitelmanand;#39;s not-so-benign syndrome. N Engl J Med 2005; 353: 850-851.&#13;
Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartterand;#39;s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996b; 13: 183-188.&#13;
Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP. Gitelmanand;#39;s variant of Bartterand;#39;s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996a; 12: 24-30.&#13;
Tang H, Zhang X, Zhang J, Li Y, Del Gobbo LC, Zhai S, Song Y. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 2016; 59: 2546-2551.&#13;
Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, Grisart B, Bridoux F, Unwin R, Moulin B, Haymann JP, Vantyghem MC, Rigothier C, Dussol B, Godin M, Nivet H, Dubourg L, Tack I, Gimenez-Roqueplo AP, Houillier P, Blanchard A, Devuyst O, Jeunemaitre X. Spectrum of mutations in Gitelman syndrome. J Am Soc Nephrol 2011; 22: 693-703.&#13;
Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 2014; 30: 1759-1768.&#13;
Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother 1994; 28: 220-226.</References>